# Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping

> **NCT03548766** · PHASE3 · UNKNOWN · sponsor: **Hamad Medical Corporation** · enrollment: 12 (estimated)

## Conditions studied

- Blood Disease
- Blood Transfusion, Autologous
- Blood Doping
- Blood Transfusion, Homologous

## Interventions

- **BIOLOGICAL:** Homologous Blood Transfusion
- **BIOLOGICAL:** Autologous Blood Transfusion

## Key facts

- **NCT ID:** NCT03548766
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-20
- **Primary completion:** 2021-12
- **Final completion:** 2021-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2020-08-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03548766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03548766, "Using DNA-Typing and Erythrocyte Microparticle Analysis to Detect Blood Doping". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03548766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*